When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BDTX - Black Diamond: High-Risk High-Reward Low-Profile EGFR Inhibitor Worth A Deep Dive
Black Diamond Therapeutics Inc.
2024-06-27 10:38:07 ET
Summary
Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer.
BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data readouts expected in 2024 and early 2025.
Black Diamond Therapeutics has a strong-enough cash position for now, but the success of their pipeline candidates will be crucial for long-term sustainability.